1Q Revenues: $5.6 billion (flat)
1Q Earnings: $2.0 billion (-14%)
Comments: Enbrel sales increased 4% to $1.2 billion. Prolia sales increased 20% to $592 million. XGEVA sales increased 6% to $471 million. KYPROLIS sales increased 10% to $245 million. Repatha sales increased 15% to $141 million. Parsabiv sales increased 207% to $126 million driven by higher unit demand, offset partially by net selling price. Vectibix sales increased 1% to $170 million. Nplate sales increased 6% to $189 million. BLINCYTO sales increased 41% to $69 million. Neulasta sales were down 12% driven primarily by lower net selling price and, to a lesser extent, changes in inventory. NEUPOGEN sales were down 29% primarily due to the impact of competition on unit demand and net selling price. EPOGEN sales decreased 10% driven primarily by lower net selling price. Aranesp sales decreased 9% due to competition. Sensipar/Mimpara sales were down 57% due to competition.